Outset Medical, Inc.
NASDAQ:OMMedical - Devices
+$0.73 today
- Market cap
- $57.31M
- Beta
- 1.94
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$4.07
Volume 0.05M
Average 0.16M
OM Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Outset Medical, Inc.NASDAQ: OM
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables turns positive
Q1 FY2026 accounts payables was $865K, compared with -$2.77M a year earlier. Trailing-twelve-month accounts payables was $344K. Over 3 fiscal years it compounded at +37.0% a year.
Context
- Accounts payables amounted to 2.8% of revenue in FY2025, up 1.0 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts payables holds near $865K or moves back toward the trailing-twelve-month quarterly average of $86K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (3.29M) USD
- Year-over-year change
- -69.0%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.29M) | -69.0% |
| FY2024 | 2024-12-31 | (1.95M) | -136.7% |
| FY2023 | 2023-12-31 | 5.31M | +514.7% |
| FY2022 | 2022-12-31 | (1.28M) | +58.2% |
| FY2021 | 2021-12-31 | (3.07M) | — |
Accounts Payables vs competitors
How OM compares with its peers on the latest reported figures
- OM's LTM Mar 2026 accounts payables of $344K is the 9th largest of the 10 companies compared; the peer median is $890K.
- Its year-over-year change of +108.3% is the 5th highest of 9, against a peer median of +68.0%.
- Accounts payables amounts to 0.3% of revenue for OM, versus a peer median of 4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $5.77M | -364.9% | -53.8% | 4.0% | |
| LTM Mar 2026 | $2.63M | -232.5% | -6.1% | 0.7% | |
| LTM Mar 2026 | $2.51M | +12.5% | — | 1116.0% | |
| LTM Mar 2026 | $2.36M | -321.8% | — | 381.1% | |
| LTM Mar 2026 | $2.27M | — | — | 4.2% | |
| LTM Mar 2026 | $890K | +150.0% | -41.1% | 2.0% | |
| LTM Mar 2026 | $885K | +342.5% | — | 0.3% | |
| LTM Mar 2026 | $841K | +141.0% | — | 8.8% | |
| LTM Mar 2026 | $344K | +108.3% | +37.0% | 0.3% | |
| LTM Dec 2025 | $306.99K | +123.6% | -15.0% | 2.4% | |
| Peer median (excluding OM) | $890K | +68.0% | -28.1% | 4.0% | |
Competitors are the stored peer set for OM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (131.94M) | (162.96M) | (172.8M) | (127.98M) | (81.65M) |
| Depreciation & Amortization | 5.16M | 5.17M | 5.81M | 5.73M | 4.34M |
| Deferred Income Tax | 3.08M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 17.45M | 27.2M | 38.63M | 29.36M | 15.62M |
| Change in Working Capital | (25.6M) | (21.14M) | (773K) | (25.69M) | 2.2M |
| Accounts Receivables | (19.14M) | (2.51M) | (5.09M) | (5.01M) | 3.78M |
| Inventory | (22.04M) | (14.73M) | 1.65M | (10.86M) | 11.79M |
| Accounts Payables | (3.07M) | (1.28M) | 5.31M | (1.95M) | (3.29M) |
| Other Working Capital | 18.64M | (2.63M) | (2.64M) | (7.87M) | (10.08M) |
| Other Non-Cash Items | 1.59M | 6M | (2.25M) | 2.28M | 13.17M |
| Operating Cash Flow | (130.26M) | (145.73M) | (131.37M) | (116.3M) | (46.33M) |
| Capital Expenditures | (3.11M) | (8.33M) | (3.44M) | (912K) | (798K) |
| Acquisitions (Net) | 139.4M | 57.97M | 0 | 0 | 0 |
| Purchases of Investments | (178.43M) | (261.15M) | (172.28M) | (156.58M) | (221.97M) |
| Sales of Investments | 39.03M | 203.18M | 258.75M | 261.43M | 125.08M |
| Other Investing Activities | (139.4M) | (57.97M) | 0 | 0 | 0 |
| Investing Cash Flow | (142.51M) | (66.3M) | 83.03M | 103.94M | (97.68M) |
| Debt Repayment | 0 | 64.86M | 33.23M | 66.52M | (106.68M) |
| Common Stock Issued | 149.09M | 8.04M | 10.43M | 2.28M | 162.19M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 11.06M | 0 | 0 | (938K) | 0 |
| Financing Cash Flow | 160.15M | 72.9M | 43.65M | 67.87M | 55.5M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (112.62M) | (139.13M) | (4.7M) | 55.51M | (88.51M) |
| Free Cash Flow | (133.37M) | (154.05M) | (134.81M) | (117.22M) | (47.13M) |
Outset Medical, Inc.
NASDAQ:OM
Intrinsic Alpha fair value
Locked
Current Price
$3.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.